Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Astellas Pharma (ALPMY) recently announced the launch of Astagraf XL (tacrolimus extended-release capsules) in the U.S.

Astagraf XL was approved in the U.S. in Jul 2013 for the prophylaxis of organ rejection in patients receiving a kidney transplant used with mycophenolate mofetil (MMF) and corticosteroids, with or without basiliximab induction.

As per Astellas, Astagraf XL is the first once-daily oral tacrolimus formulation to be marketed in the U.S. for the prevention of organ rejection in patients receiving a kidney transplant.

We remind investors that approval was based on positive results from two primary, randomized, comparative phase III studies which enrolled 1,093 patients in the U.S., Europe, Canada, South America, Australia and South Africa.

This drug is already approved in the EU since 2007 under the trade name Advagraf and in Japan since 2008 under the trade name Graceptor.

Astagraf XL should help replace some of the sales lost to generic competition for Prograf (tacrolimus). Prograf is approved in the U.S, to prevent organ rejection in patients who have had a kidney, liver or heart transplant.

We are encouraged by the company’s efforts to expand geographically. Last month, Astellas launched its prostate cancer drug, Xtandi, in the UK.

The launch of these drugs in additional markets should boost the top-line in fiscal 2013. The company expects sales of ¥1.17 billion in fiscal 2013. We expect further updates on the same when the company announces second quarter results.

Astellas carries a Zacks Rank #3 (Hold). Right now, Jazz Pharmaceuticals (JAZZ - Analyst Report), Shire (SHPG - Analyst Report) and Ironwood Pharmaceuticals (IRWD - Analyst Report) look well positioned, each with a Zacks Rank #2 (Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
BITAUTO HOLD BITA 35.33 +14.82%
ANI PHARMACE ANIP 24.79 +14.66%
E HOUSECHINA EJ 10.99 +9.24%
CANADIAN SOL CSIQ 26.97 +7.15%
INTERNATIONA ICAGY 33.30 +5.38%